Martin Auster

Martin Auster joined Raymond James in 2025 and covers the biotechnology industry. Previously, he served as chief financial officer at Ventyx biosciences from 2021-2024 and was a research analyst at UBS Securities LLC from 2016-2017 and at Credit Suisse Securities (USA) LLC from 2017-2021. Prior to that, Dr. Auster held the positions of chief business officer at Ascendis Pharma from 2014- 2016 and VP-business development & strategic finance at United Therapeutics Corp. from 2009-2014. Earlier in his career, he served as a senior equity analyst at Truist Securities, Inc., as a senior biotechnology analyst at Wachovia Securities LLC, and as a portfolio manager at GLG Partners, Inc. Dr. Auster completed his undergraduate degree at the University of Michigan and obtained a doctorate from the University of Texas Medical Branch at Galveston.